Navigating Data for Tafasitamab- and Epcoritamab-Based Therapy in R/R Follicular Lymphoma

Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, examine clinical trial data supporting tafasitamab- and epcoritamab-based approaches in relapsed/refractory follicular lymphoma. Nastoupil highlights findings from the phase 3 inMIND trial and subsequent subgroup analyses that reinforce the efficacy of tafasitamab plus R². Mehta discusses how these data compare with bispecific antibody strategies and where these regimens may fit relative to CAR T-cell therapy.